Business Wire

KAYTUS

23.5.2024 09:40:31 CEST | Business Wire | Press release

Share
KAYTUS Launches K22V2 Server, Pioneering New Architecture of 2U Half-Width Ultra Efficiency

KAYTUS, a leading IT infrastructure provider, launched at ISC High Performance 2024 the K22V2, a multi-node server with exceptional compute density and energy efficiency. The K22V2 integrates two independent hot-swap single-socket compute nodes in a 2U form factor. Each node supports either a 4th Gen AMD EPYC™ 9004 series processor with 12 DDR5 RDIMMs (4800MHz) or a 5th Gen Intel® Xeon® processor with eight DDR5 RDIMMs (5600MHz), offering flexible storage and I/O configurations. Each node also supports 6 SATA/NVMe SSDs or 8 E1.S SSDs, along with 4 PCIe 5.0 slots and one OCP NIC 3.0. This makes it an optimal choice for compute-intensive applications, suitable for customers seeking both high compute density and cooling efficiency.

Advanced 1U Computing Density Enhanced by 2U Cooling and O&M Efficiency

Focused on energy efficiency, K22V2 is fitted to accommodate two single-socket nodes within a 2U space, in a horizontal layout. Each node functions as an autonomous server system, enabling independent hot maintenance with plug-and-play support to minimize disruption, thus significantly enhancing O&M efficiency. This design is advantageous for opting for 2U high efficiency heatsinks. A 2U heatsink, due to its effective utilization of vertical space, features a length merely one-fifth that of a 1U heatsink, facilitating a more efficient server layout. Furthermore, the air flow resistance of a 1U heatsink is four times that of a 2U counterpart at the same air volume (50 CFM), necessitating fans with higher power.

According to testing data, the cooling efficiency of the server in a 2U space is superior when two single-socket nodes are horizontally arranged in parallel compared to when two 1U single-socket nodes are vertically stacked. The K22V2 demonstrates 40% better cooling efficiency compared to two standard 1U rack servers under the same computing conditions, while also reducing power consumption by up to 8%.

New pioneering architecture delivers better cost performance efficiency

The K22V2 server features a streamlined modular design where two nodes share the chassis, backplane, fan, and PSU, providing significant L6 cost advantages compared to products with two independent nodes. This pioneering architecture is optimized for high-performance single-socket processors and addresses the issue of high migration costs associated with a single server failure impacting multiple tasks. Consequently, the K22V2 is versatile, supporting a wide range of typical applications from computing to big data, and is ideal for scenarios requiring demanding computing density and cooling efficiency. Additionally, it offers users more convenient O&M.

System Overview

KAYTUS K22V2 Multi-node server

(Side by side)

Normal 2x 1U servers

(Stack up)

System Configuration

System depth

880 mm

850 mm

CPU Heatsink

2U EVAC

1U EVAC

Fan

6056*6

4056*8

CPU Power (EGS)

300W

300W

CPU Core Count

104

208

Thermal Evaluation Result

Fan Duty

50%

70%

Total Fan Power

83.6W

268.8W

Fan Power/Per CPU

41.8W

67.2W

Note

All thermal evaluations are based on conditions of a 35°C ambient temperature, sea level, and a normally operating fan.

About KAYTUS

KAYTUS is a leading provider of IT infrastructure solutions, delivering a diverse range of cutting-edge, open, and eco-friendly products for cloud, AI, edge computing, and other emerging applications. With a customer-centric approach, KAYTUS is agile and responsive to user needs through its adaptable business model. Discover more at KAYTUS.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523837473/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fourthline and Veridas Complete Merger to Create a European Leader in Bank-Grade Digital Identity3.11.2026 13:40:00 CET | Press release

One provider for identity, compliance and fraud prevention across 50+ countries, with a single integrated platform. Fourthline and Veridas combined will create a global bank-grade identity platform: sovereign AI, modular compliance, and proprietary anti-fraud and biometric technology across Europe, Latin America, and the US; on track for 200 million verifications in 2026. With a projected combined revenue of more than €50m in 2026 and both businesses EBITDA-positive at closing, the company expects to reach €85m annual recurring revenue in 2029. Financials: The transaction includes funding of up to €65m provided by existing shareholder Finch Capital, new equity investment from Seaya Andromeda and debt financing from Ashgrove Capital. Fourthline and Veridas today announce the completion of their merger, first announced on 16 July 2026. The transaction closed on 3 November 2026 following the satisfaction of all closing conditions. This press release features multimedia. View the full rele

Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights3.11.2026 12:30:00 CET | Press release

Final NDA submission nearing completion and will be filed in the next two weeks Launch readiness on track for expected launch in H12027, subject to FDA approval Data from two positive Phase 3 trials reinforce COMP360's unique and highly differentiated profile of rapid onset and durability of effect with 52-week open label data from COMP005 showing notable added benefit from an additional COMP360 25 mg dose extending durability out to one year The Phase 3 data supports the belief that COMP360 has the potential to establish a new standard of care in TRD that can be life-changing for patients − moving beyond daily or frequent administration toward an option that could provide durable benefit with just a few treatments a year COMP360 expected to be a blockbuster opportunity with an estimated 4 million people in the U.S. living with TRD, a significantly underserved market where the only marketed medicine has captured <3% market share COMP360 expected to fit seamlessly into current treatment

Vedanta Limited Delivers Highest-ever Half-yearly Profit of $1.21 bn, up 151% YoY3.11.2026 12:26:00 CET | Press release

Indian multinational Vedanta Limited (BSE: 500295 & NSE: VEDL), a global leader in metals and critical minerals, announced its consolidated results for the second quarter and half year ended 30 September 2026, delivering its best-ever financial performance driven by operational excellence and disciplined execution. Vedanta Limited achieved its highest-ever quarterly Profit of $649 mn, up 151% YoY, while half-yearly Profit reached a record $1.21 bn, up 151% YoY. Vedanta also declared its first interim dividend of INR 5 per share during the quarter, reinforcing its commitment to shareholder returns. The Company delivered record quarterly revenue of $2.70 bn, up 57% YoY, taking half-yearly revenue to a record $5.18 bn, up 54% YoY. Quarterly EBITDA surged 106% YoY to $1.04 bn, while half-yearly EBITDA reached a record $1.94 bn, up 103% YoY. EBITDA margins expanded to 60% in Q2 and 58% in H1, improving by 1,055 bps and 1,023 bps YoY, respectively. Vedanta further strengthened its balance sh

BeOne Medicines to Present at the Jefferies Global Healthcare Conference3.11.2026 12:01:00 CET | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026, with a fireside chat at 9:30 a.m. GMT. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.b

Dubai Culture Unveils ISEA2026 Online Academic Programme3.11.2026 11:58:00 CET | Press release

Dubai Culture and Arts Authority has unveiled the academic programme for the 31st International Symposium on Electronic/Emerging Art (ISEA2026), taking place in Dubai from 6 to 15 November 2026 under the theme ‘ELYAH: Constellating Place, Data, and Identity’. The symposium will explore the intersections of art, science and technology and examine the future of electronic arts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103057351/en/ Dubai Culture unveils ISEA2026 Online Academic Programme (Photo: AETOSWire) The symposium, organised by Dubai Culture in partnership with Zayed University, is set to be the largest edition in its history. It will feature opening remarks by Her Highness Sheikha Latifa bint Mohammed bin Rashid Al Maktoum, Chairperson of Dubai Culture, and Her Excellency Hala Badri, Director General of Dubai Culture, alongside keynote presentations by Katherine Hayles, Distinguished Research Professor at the U

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye